<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39452758</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (M<sup>pro</sup>).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">887</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13100887</ELocationID><Abstract><AbstractText>The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus M<sup>pro</sup> protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hernández-Serda</LastName><ForeName>Manuel Alejandro</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0009-0009-0702-1502</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez-Valadez</LastName><ForeName>Víctor H</ForeName><Initials>VH</Initials><Identifier Source="ORCID">0000-0002-5014-0023</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Biológicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>QSAR Analytics S.A. de C.V. Coatepec 7, Cumbria, Cuautitlán Izcalli, Ciudad de México 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguirre-Vidal</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0001-0301-4593</Identifier><AffiliationInfo><Affiliation>Laboratorio de Química Medicinal y Teórica FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Campo 1 Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markarian</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0001-8072-4268</Identifier><AffiliationInfo><Affiliation>Swine and Poultry Infectious Diseases Research Center (CRIPA), Research Group on Infectious Diseases in Production Animals (GREMIP), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Pharmacie, Université de Montréal, Montreal, QC H3T 1J4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina-Franco</LastName><ForeName>José L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-4940-1107</Identifier><AffiliationInfo><Affiliation>DIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, National Autonomous University of Mexico, Av. Universidad 3000, Ciudad de México 04510, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardenas-Granados</LastName><ForeName>Luis Alfonso</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0009-0004-8687-4143</Identifier><AffiliationInfo><Affiliation>Laboratorio de Química Medicinal y Teórica FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Campo 1 Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarcón-López</LastName><ForeName>Aldo Yoshio</ForeName><Initials>AY</Initials><Identifier Source="ORCID">0009-0008-1700-8582</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Soriano</LastName><ForeName>Pablo A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-4635-8425</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velázquez-Sánchez</LastName><ForeName>Ana María</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falfán-Valencia</LastName><ForeName>Rodolfo E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Laboratorio de Química Medicinal y Teórica FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Campo 1 Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angeles</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0068-322X</Identifier><AffiliationInfo><Affiliation>Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahamyan</LastName><ForeName>Levon</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0849-0134</Identifier><AffiliationInfo><Affiliation>Swine and Poultry Infectious Diseases Research Center (CRIPA), Research Group on Infectious Diseases in Production Animals (GREMIP), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RI000486</GrantID><Agency>Quebec Ministry of International Relations and Francophonie; Quebec-Mexico collaboration project (Groupe de travail Québec-Mexique, 2021-2023)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3CLpro</Keyword><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">Nsp5</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39452758</ArticleId><ArticleId IdType="pmc">PMC11510711</ArticleId><ArticleId IdType="doi">10.3390/pathogens13100887</ArticleId><ArticleId IdType="pii">pathogens13100887</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu H., Wei L., Niu P. The novel coronavirus outbreak in Wuhan, China. Glob. Health Res. Policy. 2020;5:6. doi: 10.1186/s41256-020-00135-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41256-020-00135-6</ArticleId><ArticleId IdType="pmc">PMC7050114</ArticleId><ArticleId IdType="pubmed">32226823</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Li X., Li T., Zhang S., Wang L., Wu X., Liu J. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur. J. Clin. Microbiol. Infect. Dis. 2020;39:1629–1635. doi: 10.1007/s10096-020-03899-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03899-4</ArticleId><ArticleId IdType="pmc">PMC7180649</ArticleId><ArticleId IdType="pubmed">32333222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157–160. doi: 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyah Y., Benjelloun M., Lairini S., Lahrichi A. COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education. Sci. World J. 2022;2022:5578284. doi: 10.1155/2022/5578284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5578284</ArticleId><ArticleId IdType="pmc">PMC8767375</ArticleId><ArticleId IdType="pubmed">35069037</ArticleId></ArticleIdList></Reference><Reference><Citation>W.H.O  Weekly Epidemiological Update on COVID-19. 15 July 2024.  [(accessed on 17 July 2024)].  Available online:  https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-169.</Citation></Reference><Reference><Citation>Weiss S.R., Leibowitz J.L. Coronavirus pathogenesis. Adv. Virus Res. 2011;81:85–164. doi: 10.1016/B978-0-12-385885-6.00009-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385885-6.00009-2</ArticleId><ArticleId IdType="pmc">PMC7149603</ArticleId><ArticleId IdType="pubmed">22094080</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Khan S., Tiwari R., Sircar S., Bhat S., Malik Y.S., Singh K.P., Chaicumpa W., Bonilla-Aldana D.K., Rodriguez-Morales A.J. Coronavirus Disease 2019-COVID-19. Clin. Microbiol. Rev. 2020;33:e00028-20. doi: 10.1128/CMR.00028-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00028-20</ArticleId><ArticleId IdType="pmc">PMC7405836</ArticleId><ArticleId IdType="pubmed">32580969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X.L., Jia Q.L., To S.F. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae) In: Dennis H.B., Mark Z., editors. Encyclopedia of Virology. 4th ed. Academic Press; Oxford, UK: 2021. pp. 428–440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-809633-8.21501-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamoorthy S., Swain B., Verma R.S., Gunthe S.S. SARS-CoV, MERS-CoV, and 2019-nCoV viruses: An overview of origin, evolution, and genetic variations. Virusdisease. 2020;31:411–423. doi: 10.1007/s13337-020-00632-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-020-00632-9</ArticleId><ArticleId IdType="pmc">PMC7567416</ArticleId><ArticleId IdType="pubmed">33102628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., et al. Genomic characterisation and epidemiology of 2019 novel Coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi V., Saxena S., Panda P.S. Basic virology of SARS-CoV 2. Indian J. Med. Microbiol. 2022;40:182–186. doi: 10.1016/j.ijmmb.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmmb.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8919811</ArticleId><ArticleId IdType="pubmed">35300895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jungreis I., Sealfon R., Kellis M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 2021;12:2642. doi: 10.1038/s41467-021-22905-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22905-7</ArticleId><ArticleId IdType="pmc">PMC8113528</ArticleId><ArticleId IdType="pubmed">33976134</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo N., Zaldivar-Lopez S., Garrido J.J., Montoya M. SARS-CoV-2 Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns. Front. Immunol. 2021;12:708264. doi: 10.3389/fimmu.2021.708264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.708264</ArticleId><ArticleId IdType="pmc">PMC8293742</ArticleId><ArticleId IdType="pubmed">34305949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariano G., Farthing R.J., Lale-Farjat S.L.M., Bergeron J.R.C. Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Front. Mol. Biosci. 2020;7:605236. doi: 10.3389/fmolb.2020.605236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.605236</ArticleId><ArticleId IdType="pmc">PMC7773825</ArticleId><ArticleId IdType="pubmed">33392262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastogi M., Pandey N., Shukla A., Singh S.K. SARS coronavirus 2: From genome to infectome. Respir. Res. 2020;21:318. doi: 10.1186/s12931-020-01581-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01581-z</ArticleId><ArticleId IdType="pmc">PMC7706175</ArticleId><ArticleId IdType="pubmed">33261606</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B., Urakova N., Snijder E.J., Campbell E.A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 2022;23:21–39. doi: 10.1038/s41580-021-00432-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId><ArticleId IdType="pmc">PMC8613731</ArticleId><ArticleId IdType="pubmed">34824452</ArticleId></ArticleIdList></Reference><Reference><Citation>Triggle C.R., Bansal D., Ding H., Islam M.M., Farag E., Hadi H.A., Sultan A.A. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front. Immunol. 2021;12:631139. doi: 10.3389/fimmu.2021.631139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.631139</ArticleId><ArticleId IdType="pmc">PMC7952616</ArticleId><ArticleId IdType="pubmed">33717166</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong L.A., Lange S.M., Dee Cesare V., Matthews S.P., Nirujogi R.S., Cole I., Hope A., Cunningham F., Toth R., Mukherjee R., et al. Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS ONE. 2021;16:e0253364. doi: 10.1371/journal.pone.0253364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253364</ArticleId><ArticleId IdType="pmc">PMC8284666</ArticleId><ArticleId IdType="pubmed">34270554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S., Ekanayake K.B., Otting G., Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg. Med. Chem. Lett. 2022;62:128629. doi: 10.1016/j.bmcl.2022.128629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2022.128629</ArticleId><ArticleId IdType="pmc">PMC8856729</ArticleId><ArticleId IdType="pubmed">35182772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409–412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q., Xiong Y., Zhu G.H., Zhang Y.N., Zhang Y.W., Huang P., Ge G.B. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. MedComm. 2022;3:e151. doi: 10.1002/mco2.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.151</ArticleId><ArticleId IdType="pmc">PMC9283855</ArticleId><ArticleId IdType="pubmed">35845352</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simon-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19—Final Report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martin-Quiros A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward D.J., Kim C., Fischbach J., Muschiol S., Ehling R.A., Bjorkstrom N.K., Karlsson Hedestam G.B., Reddy S.T., Albert J., Peacock T.P., et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect. Dis. 2022;22:1421–1422. doi: 10.1016/S1473-3099(22)00524-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00524-2</ArticleId><ArticleId IdType="pmc">PMC9436366</ArticleId><ArticleId IdType="pubmed">36058228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S., Klein J., Robertson A., Pena-Hernandez M.A., Lin M.J., Roychoudhury P., Lu P., Fournier J., Ferguson D., Mohamed Bakhash S.A., et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. medRxiv. 2021 doi: 10.1038/s41467-022-29104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29104-y</ArticleId><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Iketani S., Nair M.S., Li Z., Mohri H., Wang M., Yu J., Bowen A.D., Chang J.Y., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgnanesi D., Heinrichs E.J., Mele A.R., Wilkinson S., Zhou S., Kulp J.L., 3rd A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery. Antiviral. Res. 2015;123:204–215. doi: 10.1016/j.antiviral.2015.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.014</ArticleId><ArticleId IdType="pubmed">26477294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwoski G., Kothiwale S., Meiler J., Lowe E.W., Jr. Computational methods in drug discovery. Pharmacol. Rev. 2014;66:334–395. doi: 10.1124/pr.112.007336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.112.007336</ArticleId><ArticleId IdType="pmc">PMC3880464</ArticleId><ArticleId IdType="pubmed">24381236</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratov E.N., Amaro R., Andrade C.H., Brown N., Ekins S., Fourches D., Isayev O., Kozakov D., Medina-Franco J.L., Merz K.M., et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem. Soc. Rev. 2021;50:9121–9151. doi: 10.1039/D0CS01065K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0CS01065K</ArticleId><ArticleId IdType="pmc">PMC8371861</ArticleId><ArticleId IdType="pubmed">34212944</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A., Sellner M., Neranjan S., Smiesko M., Lill M.A. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds. Int. J. Mol. Sci. 2020;21:3626. doi: 10.3390/ijms21103626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103626</ArticleId><ArticleId IdType="pmc">PMC7279339</ArticleId><ArticleId IdType="pubmed">32455534</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 2020;38:379–381. doi: 10.1038/d41587-020-00003-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41587-020-00003-1</ArticleId><ArticleId IdType="pubmed">32205870</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov S.D., Diderich R., Sobanski T., Pavlov T.S., Chankov G.V., Chapkanov A.S., Karakolev Y.H., Temelkov S.G., Vasilev R.A., Gerova K.D., et al. QSAR Toolbox—Workflow and major functionalities. SAR QSAR Environ. Res. 2016;27:203–219. doi: 10.1080/1062936X.2015.1136680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1062936X.2015.1136680</ArticleId><ArticleId IdType="pubmed">26892800</ArticleId></ArticleIdList></Reference><Reference><Citation>QSAR Toolbox.  [(accessed on 2 October 2021)].  Available online:  https://qsartoolbox.org.</Citation></Reference><Reference><Citation>Anastasiu D.C., Karypis G. Efficient identification of Tanimoto nearest neighbors. Int. J. Data Sci. Anal. 2017;4:153–172. doi: 10.1007/s41060-017-0064-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41060-017-0064-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Citarella A., Scala A., Piperno A., Micale N. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules. 2021;11:607. doi: 10.3390/biom11040607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11040607</ArticleId><ArticleId IdType="pmc">PMC8073203</ArticleId><ArticleId IdType="pubmed">33921886</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.W., Yiu C.B., Wong K.Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 2020;9:129. doi: 10.12688/f1000research.22457.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.22457.2</ArticleId><ArticleId IdType="pmc">PMC7062204</ArticleId><ArticleId IdType="pubmed">32194944</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242. doi: 10.1093/nar/28.1.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.235</ArticleId><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemical Computing Group, ULC . Molecular Operating Environment (MOE) 2022.02. Chemical Computing Group, ULC; Montreal, QC, Canada: 2022.</Citation></Reference><Reference><Citation>Mengist H.M., Dilnessa T., Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front. Chem. 2021;9:622898. doi: 10.3389/fchem.2021.622898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.622898</ArticleId><ArticleId IdType="pmc">PMC8056153</ArticleId><ArticleId IdType="pubmed">33889562</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkamer A., Kuhn D., Grombacher T., Rippmann F., Rarey M. Combining global and local measures for structure-based druggability predictions. J. Chem. Inf. Model. 2012;52:360–372. doi: 10.1021/ci200454v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci200454v</ArticleId><ArticleId IdType="pubmed">22148551</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens J. Determining druggability. Nat. Rev. Drug Discov. 2007;6:187. doi: 10.1038/nrd2275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2275</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel M., Visnes T., Homan E.J., Seashore-Ludlow B., Hedenstrom M., Wiita E., Vallin K., Paulin C.B.J., Zhang J., Wallner O., et al. Computational and Experimental Druggability Assessment of Human DNA Glycosylases. ACS Omega. 2019;4:11642–11656. doi: 10.1021/acsomega.9b00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.9b00162</ArticleId><ArticleId IdType="pmc">PMC6682003</ArticleId><ArticleId IdType="pubmed">31460271</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel C.N., Jani S.P., Prasanth Kumar S., Modi K.M., Kumar Y. Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus. Comput. Biol. Med. 2022;151:106318. doi: 10.1016/j.compbiomed.2022.106318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.106318</ArticleId><ArticleId IdType="pmc">PMC9673090</ArticleId><ArticleId IdType="pubmed">36423529</ArticleId></ArticleIdList></Reference><Reference><Citation>CoVariants SARS-CoV-Mutations and Variants of Interest.  [(accessed on 31 October 2023)].  Available online:  https://covariants.org/</Citation></Reference><Reference><Citation>Dierynck I., Van Marck H., Van Ginderen M., Jonckers T.H., Nalam M.N., Schiffer C.A., Raoof A., Kraus G., Picchio G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob. Agents Chemother. 2011;55:5723–5731. doi: 10.1128/AAC.00748-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00748-11</ArticleId><ArticleId IdType="pmc">PMC3232804</ArticleId><ArticleId IdType="pubmed">21896904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaldor S.W., Kalish V.J., Davies J.F., 2nd, Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., et al. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997;40:3979–3985. doi: 10.1021/jm9704098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9704098</ArticleId><ArticleId IdType="pubmed">9397180</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam R., Parves M.R., Paul A.S., Uddin N., Rahman M.S., Mamun A.A., Hossain M.N., Ali M.A., Halim M.A. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2. J. Biomol. Struct. Dyn. 2021;39:3213–3224. doi: 10.1080/07391102.2020.1761883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1761883</ArticleId><ArticleId IdType="pmc">PMC7232885</ArticleId><ArticleId IdType="pubmed">32340562</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Leist S.R., Schafer A., Won J., Brown A.J., Montgomery S.A., Hogg A., Babusis D., Clarke M.O., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13940-6</ArticleId><ArticleId IdType="pmc">PMC6954302</ArticleId><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanasi A., Mazzolini M., Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip. Respir. Med. 2017;12:7. doi: 10.1186/s40248-017-0088-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40248-017-0088-1</ArticleId><ArticleId IdType="pmc">PMC5359817</ArticleId><ArticleId IdType="pubmed">28331610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M.W., Montaner J.S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 2011;43:375–388. doi: 10.3109/07853890.2011.572905.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853890.2011.572905</ArticleId><ArticleId IdType="pubmed">21501034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiser J.J., Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu. Rev. Pharmacol. Toxicol. 2013;53:427–449. doi: 10.1146/annurev-pharmtox-011112-140254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-011112-140254</ArticleId><ArticleId IdType="pmc">PMC4193385</ArticleId><ArticleId IdType="pubmed">23140245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt H.H., Fattinger K.E., Ha H.R., Follath F., Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 1998;45:355–359. doi: 10.1046/j.1365-2125.1998.t01-1-00687.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.1998.t01-1-00687.x</ArticleId><ArticleId IdType="pmc">PMC1873963</ArticleId><ArticleId IdType="pubmed">9578182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura K., Tomita K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clin. Exp. Nephrol. 2012;16:44–48. doi: 10.1007/s10157-011-0506-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-011-0506-1</ArticleId><ArticleId IdType="pubmed">22038264</ArticleId></ArticleIdList></Reference><Reference><Citation>Raboisson P., de Kock H., Rosenquist A., Nilsson M., Salvador-Oden L., Lin T.I., Roue N., Ivanov V., Wahling H., Wickstrom K., et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 2008;18:4853–4858. doi: 10.1016/j.bmcl.2008.07.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.07.088</ArticleId><ArticleId IdType="pubmed">18678486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bafna K., White K., Harish B., Rosales R., Ramelot T.A., Acton T.B., Moreno E., Kehrer T., Miorin L., Royer C.A., et al. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep. 2021;35:109133. doi: 10.1016/j.celrep.2021.109133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109133</ArticleId><ArticleId IdType="pmc">PMC8075848</ArticleId><ArticleId IdType="pubmed">33984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamri M.A., Altharawi A., Alabbas A.B., Alossaimi M.A., Alqahtani S.M. Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics. Arab J. Chem. 2020;13:7224–7234. doi: 10.1016/j.arabjc.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arabjc.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7415226</ArticleId><ArticleId IdType="pubmed">34909058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci. Trends. 2020;14:69–71. doi: 10.5582/bst.2020.01020.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2020.01020</ArticleId><ArticleId IdType="pubmed">31996494</ArticleId></ArticleIdList></Reference><Reference><Citation>Purohit R., Sethumadhavan R. Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease. Interdiscip. Sci. 2009;1:320–328. doi: 10.1007/s12539-009-0043-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-009-0043-8</ArticleId><ArticleId IdType="pubmed">20640812</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyon L., Tremblay S., Bourgon L., Wardrop E., Cordingley M.G. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral. Res. 2005;68:27–35. doi: 10.1016/j.antiviral.2005.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.07.003</ArticleId><ArticleId IdType="pubmed">16122817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye G., Wang X., Tong X., Shi Y., Fu Z.F., Peng G. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376. Viruses. 2020;12:240. doi: 10.3390/v12020240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12020240</ArticleId><ArticleId IdType="pmc">PMC7077318</ArticleId><ArticleId IdType="pubmed">32098094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiselev O.I., Deeva E.G., Mel’nikova T.I., Kozeletskaia K.N., Kiselev A.S., Rusinov V.L., Charushin V.N., Chupakhin O.N. A new antiviral drug Triazavirin: Results of phase II clinical trial. Vopr. Virusol. 2012;57:9–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477247</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatib M., Pieraccini G., Innocenti M., Melani F., Mulinacci N. An insight on the alkaloid content of Capparis spinosa L. root by HPLC-DAD-MS, MS/MS and 1H qNMR. J. Pharm. Biomed. Anal. 2016;123:53–62. doi: 10.1016/j.jpba.2016.01.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2016.01.063</ArticleId><ArticleId IdType="pubmed">26874255</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A., Siddiqui S., Ahmad R., Mehrotra S., Ahmad B., Srivastava A.N. Exploring nature’s bounty: Identification of Withania somnifera as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation. J. Biomol. Struct. Dyn. 2022;40:1858–1908. doi: 10.1080/07391102.2020.1835725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1835725</ArticleId><ArticleId IdType="pmc">PMC7755033</ArticleId><ArticleId IdType="pubmed">33246398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y., Qu H., Wang S., Yan F., Wang C., Zhang M. Computational assessment of herbal medicine-derived compounds as potential inhibitors of SARS-CoV-2 main protease. J. Biomol. Struct. Dyn. 2023;41:9602–9613. doi: 10.1080/07391102.2022.2144949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2022.2144949</ArticleId><ArticleId IdType="pubmed">36373329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Kusov Y., Nian Y., Ma Q., Wang J., von Brunn A., Leyssen P., Lanko K., Neyts J., et al. alpha-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J. Med. Chem. 2020;63:4562–4578. doi: 10.1021/acs.jmedchem.9b01828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01828</ArticleId><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma G., Kumar N., Sharma C.S., Mishra S.S. In silico guided screening of active components of C. lanceolata as 3-chymotrypsin-like protease inhibitors of novel coronavirus. 3 Biotech. 2023;13:324. doi: 10.1007/s13205-023-03745-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-023-03745-2</ArticleId><ArticleId IdType="pmc">PMC10471561</ArticleId><ArticleId IdType="pubmed">37663751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280 e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., Matsuyama S., Li X., Takeda M., Kawaguchi Y., Inoue J.I., Matsuda Z. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob. Agents Chemother. 2016;60:6532–6539. doi: 10.1128/AAC.01043-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01043-16</ArticleId><ArticleId IdType="pmc">PMC5075056</ArticleId><ArticleId IdType="pubmed">27550352</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt J., Santos-Martins D., Tillack A.F., Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 2021;61:3891–3898. doi: 10.1021/acs.jcim.1c00203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c00203</ArticleId><ArticleId IdType="pmc">PMC10683950</ArticleId><ArticleId IdType="pubmed">34278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonopoulou I., Sapountzaki E., Rova U., Christakopoulos P. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Comput. Struct. Biotechnol. J. 2022;20:1306–1344. doi: 10.1016/j.csbj.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC8920478</ArticleId><ArticleId IdType="pubmed">35308802</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallakyan S., Olson A.J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 2015;1263:243–250. doi: 10.1007/978-1-4939-2269-7_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2269-7_19</ArticleId><ArticleId IdType="pubmed">25618350</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J.C., Hardy D.J., Maia J.D.C., Stone J.E., Ribeiro J.V., Bernardi R.C., Buch R., Fiorin G., Henin J., Jiang W., et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 2020;153:044130. doi: 10.1063/5.0014475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/5.0014475</ArticleId><ArticleId IdType="pmc">PMC7395834</ArticleId><ArticleId IdType="pubmed">32752662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>